Subject: DMEPOS Collaboration Inquiry Regarding CMS Final Rule: 2024 Medicare Advantage and Part D (CMS-4201-F)

Dear [Recipient's Name],

I'm [Your Name], representing the [Company Name]. We're interested in collaborating and increasing our understanding of how your Medicare Advantage plan is planning to integrate key aspects of the recent CMS Final Rule: 2024 Medicare Advantage and Part D (CMS-4201-F) into your operations. We've attached a summary of the rule for reference.

We have a few specific questions:

1. **Hospital Avoidance and Star Ratings**: How can we collaborate and assist in efforts to keep beneficiaries out of the hospital and improve Star Ratings?

2. **Utilization Management Committee**: What's your plan for establishing this committee, and what will its composition and responsibilities be?

3. **Annual Reviews**: How will the committee conduct annual reviews of utilization patterns?

4. **HME Industry Involvement**: Can a representative from the DMEPOS industry, like the American Association Homecare or [Company Name], participate in or meet with the Utilization Management Committee?

5. **90-Day Transition Period**: How will your plan implement the requirement for a 90-day transition period without prior authorization for active treatment?

6. **Prior Authorization**: The rule stipulates that a prior authorization request for a course of treatment must be valid for as long as medically reasonable and necessary. Please clarify how this will impact lifetime prior authorizations for treatment, such as oxygen therapy? When a prior approval is in place, what will be the expectation for medical necessity documentation?

7. **Provider Communication**: How will these Medicare policy changes be communicated to your network DMEPOS suppliers? When a Medicare coverage policy is not in place and you create a new policy specific to your plan, how are those policies communicated to DMEPOS suppliers?

We believe our mutual collaboration is vital to ensure the best care for your beneficiaries/our patients. I welcome the opportunity to discuss this in further detail with you. Please feel free to contact me directly at [Your Email Address] or [Your Phone Number] to discuss further.

Thank you for your commitment to beneficiary care.

Sincerely,

---

[Attached: CMS Final Rule: 2024 Medicare Advantage and Part D (CMS-4201-F) Summary]